Last checked at 
19 May 2023 11:00
Syncona Limited
Notice of Final Results
19 May 2023
Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, will announce its preliminary results for the period ended 31 March 2023 on Thursday 15 June 2023.
An in-person presentation for analysts will take place at 9.00am BST, with a webcast available on the Company's website at https://www.synconaltd.com/ or via this link. Alternatively, please contact Syncona@fticonsulting.com for details of the conference call.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Fergus Witt
Tel: +44 (0) 7714 916615
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.